Skip to content

Phase 1b Study of VERVE-201 in Patients with Refractory Hyperlipidemia

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-522617-39-00
Enrollment
10
Registered
2026-03-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory hyperlipidemia

Interventions

None listed

Sponsors

Verve Therapeutics Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 31, 2026